Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.82 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.82 |
| ▸ | THPO | P40225 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N6-Benzyladenosine SCHEMBL13966412 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL219438 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL20419317 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL15614834 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL472637 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL472635 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL23982413 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL20419282 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL3283829 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL30230333 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119614-B2 | Substitution derivatives of N6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2012-02-21 | — | — | US | claimed |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | VDF FUTURECEUTICALS, INC. (US) | 2009-08-13 | — | — | US | claimed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | claimed |
| EP-1575973-A2 | SUBSTITUTION DERIVATIVES OF N SP 6 SP -BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2005-09-21 | — | — | EP | claimed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| WO-2004058791-A2 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2004-07-15 | — | — | WO | claimed |
| EP-4747386-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE AGENTS AND USES THEREOF | Bisirna Therapeutics Pte. Ltd. (SG) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743089-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH OCRL GENE DISFUNCTION | Fondazione Telethon ETS (IT) | 2026-05-20 | — | — | EP | disclosed |
| US-20260115218-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2026-04-30 | — | — | US | disclosed |
| US-20260014184-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| US-20250359548-A1 | METHODS OF IMPROVING STRESS TOLERANCE, GROWTH AND YIELD IN PLANTS | VALENT BIOSCIENCES LLC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4633645-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | University College Cardiff Consultants Limited (GB) | 2025-10-22 | — | — | EP | disclosed |
| EP-0322242-B1 | Adenosine derivatives | GLAXO GROUP LTD (GB) | 1998-04-01 | — | — | EP | disclosed |
| US-5688774-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0755255-A1 | TREATMENT OF TOXOPLASMOSIS | UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996018398-A1 | TREATMENT OF TOXOPLASMOSIS | THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-06-20 | — | — | WO | disclosed |
| EP-0253962-B1 | USE OF ADENOSINE DERIVATIVES AS ANTI-DEMENTIA AGENTS | HOECHST JAPAN LIMITED (JP) | 1993-03-24 | — | — | EP | disclosed |
| EP-0355825-A2 | Viral treatment system | Prendergast, Patrick T. (IE) | 1990-02-28 | — | — | EP | disclosed |
| EP-0322242-A2 | Adenosine derivatives | GLAXO GROUP LIMITED (GB) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885SLC29A1 2267/4885TP53 4761/4885 |
| US-20260014184-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | ADRM1, ADORA1, ADORA2A | ADORA3 8/4885SLC29A1 284/4885TP53 61/4885 |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | GPR119, PRKAG2, PRKAG1 | ADORA3 162/4885SLC29A1 710/4885TP53 2033/4885 |
| US-20260115218-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA2B, ADORA3, ADORA2A | ADORA3 2/4885SLC29A1 299/4885TP53 400/4885 |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | GPR119, PRKAG2, GCKR | ADORA3 153/4885SLC29A1 670/4885TP53 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.